No rest for the weary: The Tipline for 7 May 2020
While the Federal Trade Commission’s divided decision to clear Abbvie/Allergan sinks in, Allergan continues to face private antitrust litigation over its efforts to maintain patent exclusivity for dry-eye medication Restasis. A New York federal judge certified a class of Restasis end-purchasers on Tuesday, expressing a high level of confidence in their economic expert’s analysis of the market for dry-eye medication. We also have an update on a record Federal Communications Commission civil penalty resulting from Sinclair’s effort to buy Tribune, and more on House Democrats’ push to ban mergers during the covid-19 pandemic. Our colleagues in London have a public holiday on Friday, so Tipline will be back in your inboxes on Monday.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10